Dr. Sasan Fazeli, MD
Claim this profileCity of Hope Medical Center
Area of expertise
Thyroid Cancer
Sasan Fazeli, MD has run 2 trials for Thyroid Cancer. Some of their research focus areas include:
Thyroid Gland Follicular Carcinoma
Sasan Fazeli, MD has run 1 trial for Thyroid Gland Follicular Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
City Of Hope Medical Center
Clinical Trials Sasan Fazeli, MD is currently running
Vemurafenib + Cobimetinib
for Thyroid Cancer
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
Recruiting
1 award
Phase 2
3 criteria
Dabrafenib + Trametinib + IMRT
for Thyroid Cancer
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
Recruiting
1 award
Phase 1
13 criteria
More about Sasan Fazeli, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Sasan Fazeli, MD has experience with
- Cobimetinib
- Vemurafenib
- Dabrafenib
- Intensity-Modulated Radiation Therapy
- Trametinib
Breakdown of trials Sasan Fazeli, MD has run
Thyroid Cancer
Thyroid Gland Follicular Carcinoma
Papillary Thyroid Cancer
Thyroid Carcinoma
BRAF Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sasan Fazeli, MD specialize in?
Sasan Fazeli, MD focuses on Thyroid Cancer and Thyroid Gland Follicular Carcinoma. In particular, much of their work with Thyroid Cancer has involved BRAF positive patients, or patients who are Stage IV.
Is Sasan Fazeli, MD currently recruiting for clinical trials?
Yes, Sasan Fazeli, MD is currently recruiting for 2 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Sasan Fazeli, MD has studied deeply?
Yes, Sasan Fazeli, MD has studied treatments such as Cobimetinib, Vemurafenib, Dabrafenib.
What is the best way to schedule an appointment with Sasan Fazeli, MD?
Apply for one of the trials that Sasan Fazeli, MD is conducting.
What is the office address of Sasan Fazeli, MD?
The office of Sasan Fazeli, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.